GeneDx Cash Flow Statement
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
67.33-0.40 (-0.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GeneDx free cash flow
In fiscal 2025, GeneDx generated $33.3 million of operating cash flow and spent $19.0 million on capital expenditures. That left free cash flow of $14.3 million, a free-cash-flow margin of 3.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
GeneDx cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Net Income | -21.02M | -52.29M | -175.77M | -548.98M | -245.39M | -241.34M | -29.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 9.60M | 7.90M | 19.70M | 50.00M | 21.81M | 11.73M | 6.41M |
| Stock-Based Compensation | 32.16M | 9.14M | -326.00K | 41.98M | 219.42M | 120.23M | 5.48M |
| Change in Working Capital | -27.57M | -28.29M | -37.67M | 41.90M | 17.66M | -4.17M | -1.74M |
| Operating Cash Flow | 33.28M | -28.50M | -180.15M | -319.15M | -190.43M | -93.13M | -18.73M |
| Capital Expenditures | -19.02M | -5.49M | -5.25M | -7.16M | -9.40M | -24.09M | -11.92M |
| Investing Cash Flow | -61.52M | -30.13M | -43.73M | -141.33M | -20.79M | -31.97M | -15.46M |
| Debt Issued | 0 | 0 | 48.55M | 0 | 0 | 15.93M | 0 |
| Financing Cash Flow | 48.02M | 44.16M | 186.24M | 197.31M | 493.73M | 129.06M | 148.01M |
| Net Change in Cash | 19.79M | -14.47M | -37.63M | -263.17M | 282.51M | 3.95M | 113.83M |
| Free Cash Flow | 14.26M | -33.99M | -185.40M | -326.31M | -199.83M | -117.22M | -30.65M |
This table shows 7 annual periods of GeneDx's cash flow statement, from FY 2025 back to FY 2019, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow WGS's reporting calendar. What is a cash flow statement?